secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-10-06T12:05:36+00:00
Accession:  0001140361-26-038728
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

PDS Biotech to Host Oct. 15 KOL Event on PDS0301 in Metastatic Colorectal Cancer
--------------------------------------------------------------------------------

- PDS Biotechnology (Nasdaq: PDSB) will host a virtual KOL event on October 15, 2026, at 8:00 AM ET featuring NCI/CCR investigator Jonathan M. Hernandez, M.D.
- Event covers clinical outcomes from PDS0301 Phase 2 trials in advanced liver-associated cancers, focusing on the metastatic colorectal cancer (mCRC) cohort.
- PDS0301 is an investigational IL-12 immunocytokine designed to bind necrotic DNA in tumors and deliver IL-12 to promote T cell and NK cell infiltration.
- Trial population includes second- and third-line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases, the majority of mCRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126038728/0001140361-26-038728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126038728/ef20083341_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer